Clinical trials: Pituitary Disease
Adult Growth Hormone Deficiency
The Effects of Growth Hormone Treatment Discontinuation in Adults on Metabolic Profile, Body Composition and Quality Of Life (GAMBOL Study)
Background Growth hormone (GH) is a hormone produced by the pituitary gland which sits at the base of the brain. In adults, GH plays an important role in keeping the bones and muscles healthy, and in regulating the levels of…
- Trial name
- GAMBOL (NCT05979480)
- Testing
- Dual energy X-ray absorptiometry (DXA)
- Where
- United Kingdom
- Volunteers
- 25 people
- Sponsor
- University Hospital Birmingham
Endocrine Diseases
Evaluation of Adults With Endocrine and Metabolic-Related Conditions
Background: There are many endocrine and metabolic-related conditions. Two well-known disorders include diabetes and thyroid disease. Some of these diseases are caused by a change in genes.
- Trial name
- NCT02830308
- Where
- United States
- Volunteers
- 1,250 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Systemic Inflammatory Response Syndrome, Hyperglycemia
The Importance of Adrenomedullin (AM) on ACTH-Cortisol-Glucose Axis
Hyperglycemia is frequent manifestations of the human metabolic response to systemic inflammatory response syndrome (SIRS),sepsis and septic shock, and are implicated in the clinical outcome.
- Trial name
- AM (NCT00459511)
- Testing
- Blood AM, IL-6, ACTH, Cortisol, Glucose and Insulin
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- University of Sao Paulo
Hypopituitarism, Pituitary Insufficiency
A Prospective Observational Study of Effect of Somatropin on Growth Hormone Deficient Adults
The Hypopituitary Control and Complications Study "HypoCCS" is a prospective, open label, global, multicentre, observational study on routine clinical care of adults with growth hormone deficiency occurring either isolated or in…
- Conditions
- Hypopituitarism, Pituitary Insufficiency, Growth Hormone Deficiency, Adult
- Trial name
- HypoCCS (NCT01088399)
- Testing
- Somatropin (rDNA origin)
- Volunteers
- 10,673 people
- Sponsor
- Eli Lilly and Company
Growth Hormone Deficiency, Pediatric, Endocrine System Diseases
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
A 26 week trial of TransCon hGH, a long-acting growth hormone product, administered once-a-week. Approximately 150 children (males and females) with growth hormone deficiency (GHD) will be included.
- Conditions
- Growth Hormone Deficiency, Pediatric, Endocrine System Diseases, Hormone Deficiency, Pituitary Diseases
- Trial name
- NCT03305016
- Testing
- TransCon hGH
- Where
- 24 sites in United States, Australia and 2 more
- Volunteers
- 146 people
- Sponsor
- Ascendis Pharma Endocrinology Division A/S
Insulin Resistance, Low Birth Weight
Effects of 3 Months of Selective Serotonin Reuptake Inhibitor (SSRI)-Treatment on Metabolism and Hypothalamic-pituitary-adrenal (HPA)-Axis in Young Men Born With Low Birth Weight
Chronic stress has been proposed to be involved the development of western life-style diseases such as cardiovascular disease and type 2 diabetes (T2DM).
- Conditions
- Insulin Resistance, Low Birth Weight, Type 2 Diabetes, Cardiovascular Disease
- Trial name
- LBW-SSRI (NCT00971815)
- Testing
- Escitalopram
- Where
- Denmark
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Adult Growth Hormone Deficiency, Endocrine System Diseases
A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency
This was a phase 3 open-label multicenter extension study designed to evaluate the long-term safety and efficacy of Lonapegsomatropin administered once-weekly.
- Conditions
- Adult Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
- Trial name
- NCT05171855
- Testing
- Lonapegsomatropin
- Where
- 85 sites in United States, Armenia and 19 more
- Volunteers
- 220 people
- Sponsor
- Ascendis Pharma Endocrinology Division A/S
Cushing's Syndrome
A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease
The study treatment period is 15 days in length and includes patients with pituitary Cushing's disease who are candidates for surgical intervention as well as and patients who have recurrent Cushing's post operatively.
- Trial name
- NCT00088608
- Testing
- SOM230 s.c.
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Novartis Pharmaceuticals
Acromegaly
Brain-gut Interaction in Irradiated Patients With Acromegaly
Acromegaly is caused by increased production of growth hormone (GH) from a usually benign pituitary tumor. The disease causes a number of complications including disturbances in glucose metabolism and about 25% of the patients…
- Trial name
- NCT02005978
- Where
- Denmark
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Acromegaly
Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly
This study will investigate the efficacy of a combination treatment with octreotide acetate and cabergoline in acromegalic patients that are only partially responsive to a somatostatin analog monotherapy
- Trial name
- NCT00376064
- Testing
- Octreotide acetate and cabergoline/Octrotide and Somavert
- Where
- 16 sites in Germany
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Acromegaly
Strict IGF-1 Control in Acromegaly
Acromegaly is a rare, chronic, and debilitating disease, usually caused by a benign tumor on the pituitary gland, which leads to excessive production of growth hormone (GH).
- Trial name
- I-Con (NCT02952885)
- Testing
- Pegvisomant
- Where
- 5 sites in Canada
- Volunteers
- 10 people
- Sponsor
- Unity Health Toronto
Turner Syndrome, Renal Insufficiency, Chronic
Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq
The main purpose of this study is to establish an optimal monitoring regimen in NutropinAq treated children, using newly developed capillary blood spot IGF-1 measurement technology.
- Conditions
- Turner Syndrome, Renal Insufficiency, Chronic, Pituitary Diseases, Dwarfism
- Trial name
- OPTIMA (NCT00234533)
- Testing
- Somatropin (rDNA origin)
- Where
- 45 sites in Belgium, Czechia and 12 more
- Volunteers
- 251 people
- Sponsor
- Ipsen
COVID-19, Low Triiodothyronine Syndrome
The Impact of Pituitary-thyroid and Pituitary-adrenal Axes Function on COVID-19 Clinical Course.
The main focus of the study is the assessment of hormonal function in the course of COVID-19 infection with special regard for trends predicting clinical events defined as primary endpoints of the study.
- Conditions
- COVID-19, Low Triiodothyronine Syndrome, Adrenal Insufficiency, Subacute Thyroiditis
- Trial name
- ENDO-COVID19 (NCT05070091)
- Where
- 2 sites in Poland
- Volunteers
- 180 people
- Sponsor
- Medical University of Gdansk
Adult Growth Hormone Deficiency, Mild Traumatic Brain Injury
Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)
The purpose of this study is to determine whether growth hormone replacement therapy (GHRT) is effective versus placebo in the improvement of Quality of Life in patients with adult growth hormone deficiency (AGHD) and mild…
- Trial name
- GRIT (NCT04867317)
- Testing
- Somatropin
- Where
- 16 sites in United States
- Volunteers
- 172 people
- Sponsor
- VA Office of Research and Development
Grade I Meningioma, Grade II Meningioma
Hypofractionated Proton Therapy for Benign Intracranial Brain Tumors, the HiPPI Study
This phase II trial studies how well hypofractionated proton or photon radiation therapy works in treating patients with brain tumors.
- Conditions
- Grade I Meningioma, Grade II Meningioma, Grade III Meningioma, Intracranial Neoplasm
- Trial name
- HiPPI (NCT04278118)
- Testing
- Hypofractionated Radiation Therapy, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Emory University
Colon Cancer Liver Metastasis, Inflammatory Response
Argipressin's Influence on Blood Loss During Hepatic Resection
Infusion of Argipressin during hepatic resection surgery may reduce blood loss. It may also reduce transfusion requirements, and mitigate the perioperative inflammatory response compared to placebo.
- Conditions
- Colon Cancer Liver Metastasis, Inflammatory Response, Vasopressin Causing Adverse Effects in Therapeutic Use
- Trial name
- ARG-01 (NCT05293041)
- Testing
- Argipressin
- Where
- Sweden
- Volunteers
- 248 people
- Sponsor
- Kristina Svennerholm
Pain, Postoperative, Analgesia
Analgesia Nociception Index (ANI) in Intracranial Surgical Anesthesia
In our study, 75 patients aged 18-80 years, classified as ASA I-II risk groups, who underwent intracranial surgery performed by the Department of Neurosurgery at Trakya University Faculty of Medicine Hospital, were included.
- Conditions
- Pain, Postoperative, Analgesia, Supratentorial Brain Tumor, Infratentorial Neoplasms
- Trial name
- ANI (NCT06752824)
- Testing
- ANALGESIA NOCICEPTION INDEX MONITORING
- Where
- Turkey (Türkiye)
- Volunteers
- 75 people
- Sponsor
- Trakya University
Growth Hormone Deficiency
Isolated Growth Hormone Deficiency and Amennorrhea
This is a case report of a 14-year old female with no menstruation history.
- Trial name
- NCT05448924
- Testing
- Hormone panel tests
- Where
- Indonesia
- Volunteers
- 1 people
- Sponsor
- Universitas Padjadjaran
Social Psychology
Neuropeptides and Social Behavior
It has long been established that interpersonal relationships can have a profound impact on health and well-being. Yet, we are still learning about the complex biological processes that contribute to positive social interactions…
- Trial name
- NCT01680718
- Testing
- Intranasal oxytocin, Intranasal vasopressin
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Acromegaly
Long Term Use of Somavert (Pegvisomant) For A Regulatory Post Marketing Commitment Plan
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors…
- Trial name
- NCT00658879
- Testing
- Somavert (Pegvisomant)
- Volunteers
- 251 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.